Experience gained by ophthalmologists at Center for Sarcoidosis control is summarized. Sarcoidosis involvement of the eyes was revealed in 36% of patients with sarcoidosis of the respiratory organs. Uveitis and dry keratoconjunctivitis typical of sarcoidosis involvement of the eyes are described. A protocol of ophthalmologic examination of sarcoidosis patients to detect ocular diseases and monitor the treatment efficacy is offered. The knowledge of ocular symptoms in sarcoidosis patients by public health ophthalmologists will help diagnose the disease at the period when there are no apparent changes, the clinical signs are hardly discernible, and only the ophthalmological picture permits the physician suspect sarcoidosis and direct the patient to a tuberculosis center.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ultrathin bronchoscopy-guided small airway biopsy for diagnosing sarcoidosis: A prospective study.
Pulmonology
December 2025
Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Hearth, Rome, Italy.
New ultrathin bronchoscopes (UTBs) enable the inspection and biopsy of small airways, potentially offering diagnostic advantages in sarcoidosis. In this prospective study, patients with suspected sarcoidosis underwent airway inspection with a UTB. Observed airway abnormalities were categorised into six predefined patterns.
View Article and Find Full Text PDFCardiac sarcoidosis; update for the heart failure specialist.
Curr Opin Cardiol
January 2025
Division of Cardiology, University of Ottawa Heart Institute, University of Ottawa, Faculty of Medicine, Tier 1 Clinical Research Chair in Cardiac Electrophysiology, Ottawa, ON, Canada.
Purpose Of Review: This review presents contemporary data on epidemiology, common presentations, investigations and diagnostic algorithms, treatment and prognosis. It particularly focuses on topics of most relevance to heart failure specialists, including what left ventricle (LV) function changes can be expected after treatment and outcomes to all standard and advanced heart failure therapies.
Recent Findings: Around 5% of sarcoidosis patients have clinically manifest cardiac sarcoidosis (CS), presenting with significant arrhythmias (such as conduction disturbances and ventricular arrhythmias) or newly developed unexplained heart failure.
Prevalence, incidence, and clinical features of cardiac involvement in patients with pulmonary sarcoidosis.
Respir Med
January 2025
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
Background: The epidemiology and characteristics of cardiac involvement in patients with pulmonary sarcoidosis remain unclear. We aimed to determine the prevalence, incidence, and clinical features of cardiac sarcoidosis in patients with pulmonary sarcoidosis.
Methods: The characteristics of patients with biopsy-proven pulmonary sarcoidosis were retrospectively evaluated.
European ILD registry algorithm for self-assessment in interstitial lung diseases (eurILDreg ASA-ILD).
PLoS One
January 2025
European IPF/ILD Registry and Biobank (eurIPFreg/bank, eurILDreg/bank), Giessen, Germany.
Background And Aims: Predicting progression and prognosis in Interstitial Lung Diseases (ILD), especially Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF), remains a challenge. Integrating patient-centered measurements is essential for earlier and safer detection of disease progression. Home monitoring through e-health technologies, such as spirometry and oximetry connected to smartphone applications, holds promise for early detection of ILD progression or acute exacerbations, enabling timely therapeutic interventions.
View Article and Find Full Text PDFDiagnostic Feasibility of Cardiac PET CT in the Evaluation of Inflammatory, Infectious, and Malignant Heart Disease.
R I Med J (2013)
February 2025
Alpert Medical School of Brown University, Department of Medicine, Division of Cardiology, Rhode Island Hospital.
Cardiac Positron Emission Tomography (PET) is a power- ful imaging tool with diverse applications in the detection and diagnosis of various cardiac conditions, including inflammatory, infectious, and neoplastic processes. Using the radiotracer 18F-fluorodeoxyglucose (18F-FDG), cardiac PET enables the identification of cardiac involvement in diseases such as sarcoidosis and severe infections affecting the heart tissue. Additionally, 18F-FDG PET is valuable in the evaluation of cardiac masses, helping to assess their metabolic activity and potential malignancy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!